AGP Picks
View all

Today in Healthcare: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Healthcare.

Press releases published on September 18, 2026

Chicago Plastic Surgeon Dr. Sam Speron Highlights the Growing Role of Natural Ingredients in Medical-Grade Skincare
Behavioral Health Market to reach USD 293.5 Billion by 2035 at 4.38% CAGR
Renal Dialysis Market to reach USD 41.38 Billion by 2035 at 5.6% CAGR
Healthcare Analytics Market to reach USD 354.90 Billion by 2035 at 20.9% CAGR
Healthcare Revenue Cycle Management Market to reach USD 140.31 Billion by 2035 at 9.50% CAGR
Health and Wellness Product Market to reach USD 1,975.77 Billion by 2035 at 9.69% CAGR
Preclinical CRO Market to reach USD 15.09 Billion by 2035 at 8.0% CAGR
LK Psychotherapy Opens Registration for Women's Trauma Recovery Group, Launches Free Self-Check Tool
Medical Oxygen Concentrators Market to reach USD 7.0 Billion by 2035 at 6.26% CAGR
Peak Performance Family Chiropractic Celebrates 10 Years in Davison with Community-Wide Anniversary Celebration
Chronic Obstructive Pulmonary Disease (COPD) Market to reach USD 72.55 Billion by 2035 at 8.50% CAGR
Axe Compute Sells Helomics AI Cancer Diagnostics Lab to DataMEDS AI, Completing Transition to Neocloud GPU-as-a-Service
LogicalDOC 9.3 Expands AI-Powered Document Processing with Object Detection and WhatsApp Integration
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Johns Hopkins USFHP is One of the Highest-Rated Health Plans in the Nation
VELA Medical Raises Awareness of New Federal Accessibility Rules for Medical Equipment
Mining the Purple Gold: 100% Pure Natural Organic Ube Powder
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Healthcare

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.